FDA asks Inamed for more breast implant information
This article was originally published in Clinica
The US FDA has asked Inamed for more information regarding its premarket approval (PMA) application for the its next generation cohesive gel-filled breast implants, Style 410. In a letter to the Santa Barbara, California company, the agency said that it needed the information to determine whether there is reasonable assurance that the implants are safe and effective for their intended use.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.